These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28776732)

  • 1. Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in Hereditary Hemorrhagic Telangiectasia.
    Chavan A; Schumann-Binarsch S; Schmuck B; Oltmer F; Geisthoff U; Hoppe F; Wirsching K; Klempnauer J; Manns M; Philip Thomas R; Köhne CH
    Am J Hematol; 2017 Nov; 92(11):E641-E644. PubMed ID: 28776732
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
    Azzopardi N; Dupuis-Girod S; Ternant D; Fargeton AE; Ginon I; Faure F; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Leguy-Seguin V; Rivière S; Corre R; Bailly S; Paintaud G
    MAbs; 2015; 7(3):630-7. PubMed ID: 25751241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-treatment versus extended treatment strategy of systemic bevacizumab in hereditary hemorrhagic telangiectasia: which is better?
    Epperla N; Kleman A; Karafin M; Foy P
    Ann Hematol; 2018 Sep; 97(9):1727-1729. PubMed ID: 29656313
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding.
    Epperla N; Kapke JT; Karafin M; Friedman KD; Foy P
    Am J Hematol; 2016 Jun; 91(6):E313-4. PubMed ID: 26994402
    [No Abstract]   [Full Text] [Related]  

  • 5. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT).
    Chavan A; Schumann-Binarsch S; Luthe L; Nickau B; Elsässer A; Kühnel T; Geisthoff U; Köhne H
    Vasa; 2013 Mar; 42(2):106-10. PubMed ID: 23485837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
    Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
    JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia.
    Vázquez C; Gonzalez ML; Ferraris A; Bandi JC; Serra MM
    PLoS One; 2020; 15(2):e0228486. PubMed ID: 32032395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.
    Huemer F; Dejaco M; Grabmer C; Melchardt T; Neureiter D; Mayer G; Egle A; Greil R; Weiss L
    Wien Klin Wochenschr; 2017 Feb; 129(3-4):141-144. PubMed ID: 27878613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.
    Epperla N; Hocking W
    Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.
    Mitchell A; Adams LA; MacQuillan G; Tibballs J; vanden Driesen R; Delriviere L
    Liver Transpl; 2008 Feb; 14(2):210-3. PubMed ID: 18236396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary hemorrhagic telangiectasia, liver disease and elevated serum testosterone (Osler-Weber-Rendu syndrome): a case report.
    Dissanayake R; Wickramarathne KP; Seneviratne SN; Perera SN; Fernando MU; Wickramasinghe VP
    BMC Res Notes; 2017 Jan; 10(1):58. PubMed ID: 28115008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report.
    Steineger J; Merckoll E; Slåstad JM; Eriksen EF; Heimdal K; Dheyauldeen S
    Laryngoscope; 2018 Mar; 128(3):593-596. PubMed ID: 28671294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab to treat complicated liver vascular malformations in hereditary hemorrhagic telangiectasia: a word of caution.
    Buscarini E; Manfredi G; Zambelli A
    Liver Transpl; 2008 Nov; 14(11):1685-6; author reply 1687-8. PubMed ID: 18975280
    [No Abstract]   [Full Text] [Related]  

  • 14. Liver involvement in hereditary hemorrhagic telangiectasia: CT and clinical findings do not correlate in symptomatic patients.
    Wu JS; Saluja S; Garcia-Tsao G; Chong A; Henderson KJ; White RI
    AJR Am J Roentgenol; 2006 Oct; 187(4):W399-405. PubMed ID: 16985112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia.
    Brinkerhoff BT; Choong NW; Treisman JS; Poetker DM
    Am J Otolaryngol; 2012; 33(3):349-51. PubMed ID: 21917353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver failure caused by hepatic angiodysplasia in hereditary hemorrhagic telangiectasia.
    Mukasa C; Nakamura K; Chijiiwa Y; Sakai H; Nawata H
    Am J Gastroenterol; 1998 Mar; 93(3):471-3. PubMed ID: 9517664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia.
    Sehl ME; M Gruber T; McWilliams JP; Marder VJ
    Am J Hematol; 2015 Jun; 90(6):561-3. PubMed ID: 25677911
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperintense basal ganglia lesions on T1-weighted images in hereditary hemorrhagic telangiectasia with hepatic involvement.
    Baba Y; Ohkubo K; Hamada K; Hokotate H; Nakajo M
    J Comput Assist Tomogr; 1998; 22(6):976-9. PubMed ID: 9843242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia-Related Bleeding and High-Output Cardiac Failure: Significant Inter-Individual Variability in the Need for Maintenance Therapy.
    Albitar HAH; Almodallal Y; Gallo De Moraes A; O'Brien E; Choby GW; Pruthi RK; Stokken JK; Kamath PS; Cajigas HR; DuBrock HM; Krowka MJ; Iyer VN
    Mayo Clin Proc; 2020 Aug; 95(8):1604-1612. PubMed ID: 32753135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypermanganesemia, hereditary hemorrhagic telangiectasia, brain abscess: the hepatic connection.
    Herrero Hernández E; Discalzi G
    Neurology; 2009 Aug; 73(5):405; author reply 405-6. PubMed ID: 19652148
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.